NewcelX Ltd. released an updated corporate presentation highlighting its Type 1 Diabetes flagship program NCEL-101 and strategic collaboration with Eledon Pharmaceuticals ahead of the Swiss Biotech Conference.
Key takeaways
Updated corporate presentation emphasizes NCEL-101 Type 1 Diabetes program integrated with Eledon's tegoprubart for immune protection.
Strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) aims to enhance graft survival and pursue functional cure for Type 1 Diabetes.
Management to present updated strategy at upcoming Swiss Biotech Conference.
NCEL-101 uses scalable stem-cell-derived islets for off-the-shelf insulin production.
Pipeline includes NCEL-201 encapsulation, NCEL-007 hypoimmune cells, and NCEL-301 device-based projects.
IND filing for NCEL-101 combination treatment planned for Q1 2027, FIH in Q2 2027.